Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

Inclusion Criteria: * Had onset of symptoms consistent with HS at least 6 months prior to Screening. * Has had active HS for at least 2 months. * Has ≥ 5 HS abscesses or inflammatory nodules at Screening. * Agrees to maintain baseline wound care and antibiotic therapy, including oral antibiotics, for the duration of the trial. * Agrees to use contraception Exclusion Criteria: * Has other skin disease or condition that can interfere with HS assessment. * Has a positive test for TB, HIV, hepatitis B and/or hepatitis C at Screening. * Has a history of retinopathy or known clinically significant cardiovascular or hematologic conditions. * Has taken any biologic drug within 3 serum half-lives. A list of potential biologics and their half-lives * Has started oral antibiotics within 28 days of Study Day 1. * Has, within 2 weeks prior to Day 1, received a medication prohibited based on cytochrome P450 (CYP3A4) interaction * Has such extensive disease that, in the opinion of the Investigator, it is difficult to discriminate between active lesions and scarring. * Has more than 15 active tunnels at Screening. * Is pregnant, nursing or considering becoming pregnant. * Has a history of malignancy except non-melanoma skin cancer or cervical carcinoma in situ.